I'd like to offer a comment on your previous question, if I may, about the cost of developing drugs. YM Biosciences is one of the group of very small companies that are in the business of taking risks in developing products, which may not be appropriate for a large pharmaceutical company.
For example, I mentioned the drug nimotuzumab, which we're developing for a very small population of patients. This is a risk that a large pharmaceutical company would not take. It's not appropriate for an organization that size.
We've been in business for 13 years. Over this history we've raised about $200 million, and all the money goes into research and development. We have no revenues at this point in time. It is critical for us to get that first drug across the goal line, so that we can continue to exist, and develop and license products coming out of universities.
There are limitations to the resources that would be made available to us, in terms of doing gigantic studies before products are approved. We do what is required by regulatory authorities here in Canada, the United States, Japan, and elsewhere to ensure the safety and effectiveness of our drugs.